Bio stocks on road to recovery
Justin Bailey
6 October 2010
Australian Financial Review
According to Sebastian Evans, fund manager at Naos Asset Management, four of five biotechnology stocks could end up turning into billion-dollar companies. Eli Lilly, Roche and Pfizer are companies to watch, with patents for their wonder drugs Viagra and Zoloft set to expire - forcing them to scour the world for a new product. Mr Evans likes Acrux, Nanosonics and ImpediMed as well, with ImpediMed a particular favourite among brokers. Nanosonics is currently waiting for approval from the US Food and Drug Administration for its Trophon EPA product. The firm has also secured a distribution agreement with General Electric?s health division and has a "buy" recommendation from the one broker covering the stock. Acrux is looking to move into AndroGel?s US market and has a implied 44 per cent return over the next year according to broker target price estimates.
Add to My Watchlist
What is My Watchlist?
